Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review

November 2025 | Volume 24 | Issue 11 | 9092 | Copyright © November 2025


Published online October 27, 2025

Rajaa Shoukfe MDa, Aaron M. Tisack MDb, Henry W. Lim MDb, Tasneem F. Mohammad MDb

aWayne State University School of Medicine, Detroit, MI
bThe Henry W. Lim, MD, Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI

Abstract
Background: Nicotinamide (niacinamide) is the water-soluble form of vitamin B3. Nicotinamide plays a crucial physiological role as a catalyst for various molecular reactions in the body and is a common over-the-counter supplement. In dermatology, oral nicotinamide has a long history of diverse applications. Oral nicotinamide mitigates ultraviolet-induced immunosuppression, serves as adjunctive therapy for blistering skin disorders, reduces inflammation and sebum in acne vulgaris, and has been used for pruritic disorders. Recent studies indicate that terminal metabolites of nicotinamide may contribute to vascular inflammation and elevate the risk of cardiovascular disease, particularly at doses exceeding therapeutic recommendations of 500 mg. Given the wide range of applications of nicotinamide in dermatology, we aim to investigate the effects of oral nicotinamide on cardiovascular health.
Methods: A review of the literature was conducted to assess the dermatological benefits of oral nicotinamide as well as its potential cardiovascular risks, particularly at high doses. Evidence from clinical trials and meta-analyses was evaluated to synthesize current knowledge on its safety and efficacy.
Results: Oral nicotinamide has demonstrated significant benefits in dermatological practice, including reducing the incidence of non-melanoma skin cancers in immunocompetent individuals and improving outcomes in various inflammatory skin conditions. However, recent evidence suggests that increased serum levels of nicotinamide's terminal metabolites N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-3-carboxamide leads to increased risk of major adverse cardiovascular effects.
Conclusion: While oral nicotinamide remains a valuable option in dermatological practice, clinicians should exercise caution in prescribing this at high doses due to the potential cardiovascular risks.

INTRODUCTION

Nicotinamide, also known as niacinamide, represents the water-soluble form of vitamin B3, while niacin, or nicotinic acid, constitutes its acidic counterpart. Nicotinamide plays a crucial role in our bodies by acting as a cofactor in enzymatic redox reactions, specifically facilitating the transfer of electrons in metabolic pathways. It is a precursor for biosynthesis of essential coenzymes involved in cellular energy production, DNA repair and other critical biochemical processes. It also inhibits PARP-1 and other molecules involved in cell signaling, which is essential for regulating DNA repair and maintaining cellular function.1 Insufficient intake of this vitamin from dietary sources can lead to pellagra, characterized by a triad of symptoms: dementia, dermatitis, and diarrhea. To avoid deficiency, the Office of Dietary Supplements within the National Institutes of Health recommends that adults consume at least 15 mg of nicotinamide per day. De novo synthesis and salvage pathways also contribute to the body's stores of this vitamin. Most individuals consume more than adequate amounts of nicotinamide daily, with the median reporting 37 mg per day, and only 4% of people consuming less than the recommended 15 mg per day.2 Although niacin and nicotinamide represent different forms of vitamin B3, they share similar end products and secondary metabolites (Figure 1). Both niacin and nicotinamide are precursors to the coenzymes nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP). Excess niacin or nicotinamide leads to increased NAD+ production, which is methylated to N-methylnicotinamide. N-methylnicotinamide is then further oxidized into N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) (Figure 1).3

Oral nicotinamide, which is used to avoid the common side effect of flushing seen with niacin, has a wide range of applications in dermatology including the treatment of blistering skin disorders, acne vulgaris, uremic pruritus, and chemoprevention of non-melanoma skin cancers (NMSC). Recent research has found an association between nicotinamide metabolites and increased